Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Handtremor
• Source: Shutterstock

Just one week after receiving US Food and Drug Administration approval to provide deep brain stimulation (DBS) surgery while patients are under general anesthesia, Medtronic plc announced the agency also has greenlighted new magnetic resonance imaging (MRI) labeling for its DBS systems.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Medtech Insight